Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.

NVP-1805R2 is under clinical development by NVP Healthcare and currently in Phase I for Unspecified Cardiovascular Disorders.

Xaluritamig is under clinical development by Amgen and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition success rate ...

CT-7439 is under development for the treatment of solid tumors including breast cancer, ovarian cancer and Ewing's Sarcoma. It acts by targeting cyclin dependent kinase 12 and 13 (CDK12 and 13). It is ...

LXE-408 is under clinical development by Novartis and currently in Phase I for Chagas Disease (American Trypanosomiasis).

Tevimbra is under clinical development by BeiGene and currently in Phase II for Muscle Invasive Bladder Cancer (MIBC).

Tebapivat is under clinical development by Agios Pharmaceuticals and currently in Phase I for Sickle Cell Disease.

Tevimbra is under clinical development by BeiGene and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase II drugs for Gallbladder Cancer have a 32% phase transition success ...

ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Metastatic Colorectal Cancer.

Rifaximin is under clinical development by Nexpharm Korea and currently in Phase I for Irritable Bowel Syndrome.

CKD-510 is under development for the treatment of Charcot-Marie-Tooth disease and atrial fibrillation. It is administered through oral route.The drug candidate is a new chemical entity targeting ...

ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Solid Tumor.